Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -64.55% is 41% below its 5-year average of -45.67%, around the middle of its 5-year range (-165.94%–-0.05%).
14244.44% below its 12-month average of -0.45%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-06-30): -17.08%.
RETURN ON ASSETS (ROA)
-64.55%
RETURN ON ASSETS (ROA) AVG TTM
-0.45%
RETURN ON ASSETS (ROA) AVG 3Y
-55.72%
RETURN ON ASSETS (ROA) AVG 5Y
-45.67%
RETURN ON ASSETS (ROA) AVG 10Y
-34.38%
RETURN ON ASSETS (ROA) AVG 15Y
-19.19%
RETURN ON ASSETS (ROA) AVG 20Y
-19.58%
CURRENT VS TTM AVG
-14244.44%
CURRENT VS 3Y AVG
-15.85%
CURRENT VS 5Y AVG
-41.33%
CURRENT VS 10Y AVG
-87.77%
CURRENT VS 15Y AVG
-236.42%
CURRENT VS 20Y AVG
-229.64%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-100.06%
vs the sector median at left
Neuphoria Therapeutics Inc.
Market Cap
$18.65M
Return on Assets (ROA)
-64.55%
TTM Avg
-0.45%
3Y Avg
-55.72%
5Y Avg
-45.67%
Market Cap
$18.41M
Return on Assets (ROA)
-15.04%
TTM Avg
-19.94%
3Y Avg
-19.35%
5Y Avg
-18.92%
Market Cap
$18.30M
Return on Assets (ROA)
-548.74%
TTM Avg
-346.44%
3Y Avg
-242.08%
5Y Avg
-167.09%
Market Cap
$19.42M
Return on Assets (ROA)
-393.39%
TTM Avg
-225.59%
3Y Avg
-343.91%
5Y Avg
-343.91%
Market Cap
$19.77M
Return on Assets (ROA)
-173.14%
TTM Avg
-158.95%
3Y Avg
-120.45%
5Y Avg
-102.27%
Market Cap
$17.39M
Return on Assets (ROA)
-39.68%
TTM Avg
-29.52%
3Y Avg
-26.86%
5Y Avg
-20.28%
Market Cap
$17.31M
Return on Assets (ROA)
-49.72%
TTM Avg
-28.29%
3Y Avg
-39.08%
5Y Avg
-40.04%
Market Cap
$16.84M
Return on Assets (ROA)
-59.70%
TTM Avg
-56.25%
3Y Avg
-61.89%
5Y Avg
-61.99%
Market Cap
$16.82M
Return on Assets (ROA)
-68.66%
TTM Avg
-45.54%
3Y Avg
-39.28%
5Y Avg
-39.25%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | $18.65M | -64.55% | -0.45% | -55.72% | -45.67% |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | -15.04% | -19.94% | -19.35% | -18.92% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | -548.74% | -346.44% | -242.08% | -167.09% |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | -393.39% | -225.59% | -343.91% | -343.91% |
| Quantum BioPharma Ltd. (QNTM)vs › | $19.77M | -173.14% | -158.95% | -120.45% | -102.27% |
| Cosmos Health Inc. (COSM)vs › | $17.39M | -39.68% | -29.52% | -26.86% | -20.28% |
| Lipocine Inc. (LPCN)vs › | $17.31M | -49.72% | -28.29% | -39.08% | -40.04% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | -59.70% | -56.25% | -61.89% | -61.99% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | -68.66% | -45.54% | -39.28% | -39.25% |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | -98.29% | -314.03% | -259.71% | -198.18% |
ROA
-64.5%
ROE
-75.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-06-30 | -0.05% |
| 2025-06-30 | -0.85% |
| 2024-06-30 | -56.03% |
| 2023-06-30 | -165.94% |
| 2022-06-30 | -35.13% |
| 2021-06-30 | -16.03% |
| 2020-06-30 | -20.65% |
| 2019-06-30 | -18.02% |
| 2018-06-30 | -38.55% |
| 2017-06-30 | -8.03% |
| 2016-06-30 | -18.87% |
| 2015-06-30 | -24.52% |
| 2014-06-30 | 4.93% |
| 2013-06-30 | -18.66% |
| 2012-06-30 | -10.08% |
| 2011-06-30 | -27.27% |
| 2010-06-30 | -26.06% |
| 2009-06-30 | -27.75% |
| 2008-06-30 | -16.90% |
| 2007-06-30 | -17.68% |
| 2006-06-30 | -27.38% |
| 2005-06-30 | -27.17% |
| 2004-06-30 | -23.89% |
| 2003-06-30 | -36.12% |
| 2002-06-30 | -22.03% |
| 2001-06-30 | -30.28% |
| 2000-06-30 | -26.73% |
| 1999-06-30 | -158.22% |
